Mark L. Baum

“We spent the first half of 2026 building demand and strengthening the commercial foundation of our business. The second half is about converting that demand into accelerating revenue and growth and profitability, and of course, hitting numbers.”

“We're really grateful for the opportunity to share the Harrow story. I think everybody can hear me hopefully. I would imagine that most people listening to this presentation are really interested in AI and at Harrow believe it or not we are an AI company.”

“To begin, as a growth-oriented business, the fuel for our success is and will always be demand. Without buyers seeing value in Harrow's products, ordering and reordering them.”

“Over the past five years, Harrow Health, Inc. has undergone a fundamental transformation. Harrow Health, Inc. now owns one of the largest portfolios of prescription ophthalmic products in the United States market.”

“As always, please review our supplemental documents for the third quarter, including our earnings release, corporate presentation and Letter to Stockholders, all of which are now available on the Investor Relations section of our corporate website.”